The first of these 'Super breeds' of medicinal cannabinoids developed in Australia, called the Cleverman will be registered with IP Australia who administer Plant Breeder's Rights.

Research Leader and Director Anthony David Bower said, "It has been demonstrated that there are something like 80 cannabinoids in the cannabis plant, and to date only a small number have been looked at in any detail."

Mullaways Medical Cannabis proposes to research and develop other cannabinoid based medicines including patches, creams, oils and edibles that have therapeutic benefits and that may be delivered more safely and effectively than by smoking cannabis.

The company also proposes to conduct research into the different methods of growing the cannabis plant and conduct research into the basic chemistry and pharmacology of cannabinoids with the aim of developing cannabinoid based medicines of an acceptable standard that may be delivered more safely and effectively than by smoking cannabis.

4 THC thresholds for psychotropic effects

Scientific matters can only be clarified by prolonged, faithful bona fide observations in friendly exchange of opinion, never by
imprisonment. A person's right to know, to learn, to inquire, to make bona fide errors, to investigate must, by all means, be safe,
if the word FREEDOM should ever be more than an empty political slogan.

In 1988 the first cannabinoid receptor was discovered and since then researchers have learned that there are two different types of cannabinoid receptors which are distributed throughout our bodies and that we make chemicals within our bodies endocannabinoids which are similar to the cannabinoids in the cannabis plant. Both plant and human cannabinoids bind to and influence these receptors in order to discourage the rise and progression of numerous disease processes.

Cannabinoid receptor type-1 (CB1) - CB1 receptors are found primarily in the brain, to be specific in the basal ganglia and in the limbic system, including the hippocampus. They are also found in the cerebellum and in both male and female reproductive systems. CB1 receptors are absent in the medulla oblongata, the part of the brain stem responsible for respiratory and cardiovascular functions. Thus, there is not the risk of respiratory or cardiovascular failure that can be produced by some drugs. CB1 receptors appear to be responsible for the euphoric and anticonvulsive effects of cannabis.

Cannabinoid receptor type-2 (CB2) - CB2 receptors are predominantly found in the immune system, or immune-derived cells with the greatest density in the spleen. While found only in the peripheral nervous system, a report does indicate that CB2 is expressed by a subpopulation of microglia in the human cerebellum. CB2 receptors appear to be responsible for the anti-inflammatory and possibly other therapeutic effects of cannabis.

The cannabinoid system is a major neurochemical system whose functional significance has only recently been explored. We are witnessing the beginning of a revolution in cannabinoid research.

The endogenous opioid system and the endocannabinoid system are co-localised in pain-processing regions and opioids and cannabinoids exert a synergistic antinociceptive effect. The ability of cannabinoids to induce antinociception in virtually every animal model of acute or persistent pain evaluated has encouraged researchers to try to better understand this important non-opioid system of analgesia.

There are currently around 80 known/discovered types of cannabinoids. In 2005 research from the University of Mississippi, USA showed cannabis contains 489 identifiable chemical compounds known to exist in the cannabis plant. At least 200 of these are cannabinoids, terpenes and flavonoids which are found in a wide range of concentrations within the flower, leaf, and stem, and which are the basis for medical and scientific use of cannabis. The cannabinoids can serve as appetite stimulants, antiemetics, antispasmodics, and have some analgesic effects.

At least 1 in 5 Australians, that's including children, live with chronic pain. Among people aged over 65, it's 1 in 3. Research shows that chronic pain left untreated leads to devastating effects on the welfare of people's lives, and the longer this goes on untreated the worse it gets. The National Pain Strategy, developed by more than 150 healthcare professionals and consumers at a 2010 national summit, recommended chronic pain be recognised as a priority health issue and constitute a disease in its own right. Yet it remains one of the most neglected areas of healthcare.

Rare disease affects more than 2 million Australians and are defined as a condition, syndrome or disorder that affects 1 in 10,000 people or less and are either life-threatening or chronically debilitating. Many are alone in their plight to tackle and come to terms with an incredibly unique, debilitating and life-threatening illness.